Development of dopamine and N-methyl-D-aspartate systems in rat brain: the effect of prenatal phencyclidine exposure

In Vitro and In Vivo Inhibition of Rat Brain Nitric Oxide Synthase Activity by Phencyclidine

Phencyclidine (PCP) is a widely abused psychoactive drug that perturbs many neurotransmitter systems studied to date. Nitric oxide (NO) has been established as a neuronal messenger and its rapid diffusibility across cell membranes makes NO an extensive and versatile messenger in brain development and functioning. The present study was initiated to investigate the effect of PCP on rat brain nitric oxide synthase (NOS) activity both in vitro and in vivo. Brain cytosolic fractions from normal rats were used for in vitro and in vivo studies. The rats were treated with a single dose of PCP (10 mg/kg, intraperitoneally); the brains were removed at 0, 1, 2, 6, and 12 hours after PCP treatment and the cytosolic fractions were prepared by homogenization and centrifugation. NOS activity was assessed by quantifying the release of [3H]-citrulline from [3H]-arginine. PCP significantly inhibited rat brain NOS in vitro in a concentration (0.05–2 mM)-dependent manner. The kinetic evaluation of arginine, NADPH, and Ca2+ activation of NOS revealed that PCP (0.5 mM) inhibited NOS activity competitively with respect to arginine and NADPH and noncompetitively inhibited with respect to Ca2+. PCP also caused a time-dependent reduction of brain NOS activity in vivo as early as 1 hour after treatment. Even after 12 hours of PCP treatment, NOS activity did not reverse to its normal level as compared to the control group, suggesting sequestration and persistence of the drug in the central nervous system. These results suggest that inhibition of brain NOS by PCP might be one of the mechanisms through which PCP causes neurotoxicity.

Speed kills: cellular and molecular bases of methamphetamine‐induced nerve terminal degeneration and neuronal apoptosis

Methamphetamine (METH) is a drug of abuse that has long been known to damage monoaminergic systems in the mammalian brain. Recent reports have provided conclusive evidence that METH can cause neuropathological changes in the rodent brain via apoptotic mechanisms akin to those reported in various models of neuronal death. The purpose of this review is to provide an interim account for a role of oxygen-based radicals and the participation of transcription factors and the involvement of cell death genes in METH-induced neurodegeneration. We discuss data suggesting the participation of endoplasmic reticulum and mitochondria-mediated activation of caspase-dependent and -independent cascades in the manifestation of METH-induced apoptosis. Studies that use more comprehensive approaches to gene expression profiling should allow us to draw more instructive molecular portraits of the complex plastic and degenerative effects of this drug.

The neuropathogenesis of HIV-1 infection

HIV encephalitis is the common pathologic correlate of HIV-dementia (HAD). HIV-infected brain mononuclear phagocytes (MP) (macrophages and microglia) are reservoirs for persistent viral infection. When activated, MP contribute to neuronal damage. Such activated and virus-infected macrophages secrete cellular and viral factors, triggering neural destructive immune responses. Our Center's laboratories have begun to decipher the molecular and biochemical pathways for MP-mediated neuronal damage in HAD. This review will discuss the salient clinical and pathological features of HAD and highlight the recent advances made, by our scientists and elsewhere, in unraveling disease mechanisms, including the role of chemokines and their receptors in the neuropathogenesis of HIV-1 encephalitis.

Inhibition of calcium ATPase by phencyclidine in rat brain

Phencyclidine (PCP) is a potent psychotomimetic drug of abuse and has profound effect on the functioning of the central nervous system (CNS). Many of the CNS functions are known to be mediated by calcium (Ca2+). In the present study we have investigated the effects of PCP on Ca2+ ATPase activity in rat brain both in vitro and in vivo. For in vitro studies, synaptic membrane fractions prepared from normal rat brain were incubated with PCP at different concentrations (25-100 microM) before the addition of substrate. For in vivo studies, rats were treated with a single moderate dose of PCP (10 mg/kg, i.p.) and animals were sacrificed at 1,2, 6 and 12 h after treatment. Ca2+ ATPase activity in synaptic membrane fractions was assayed by estimation of inorganic phosphate. PCP inhibited the Ca2+ ATPase in vitro in a concentration dependent manner with significant effect at 50 and 100 microM. A significant time-dependent reduction of the Ca2+ ATPase activity was evident in vivo. As early as 2 h after the treatment of rats with PCP the ATPase activity was significantly reduced. The reduction of Ca2+ ATPase observed even at 12 h after treatment suggesting a prolonged presence of the drug in the brain tissue. Further, kinetic studies in vitro indicated PCP to be a competitive inhibitor of Ca2+ ATPase with respect to the substrate, ATP. The present findings indicate that PCP inhibits synaptic membrane Ca2+ ATPase thus altering cellular Ca2+ homeostasis in CNS which may partially explain the pharmacological effects of the drug and/or its neurotoxicity.

Ontogeny of ethanol-induced locomotor activity and hypothermia differences in selectively bred FAST and SLOW mice

The replicate lines of selectively bred FAST and SLOW mice differ in locomotor response to 2 g/kg ethanol (EtOH). FAST mice show enhanced locomotion; SLOW mice exhibit no change or locomotor depression. Little is known about the responses of FAST and SLOW mice to EtOH during development. We assessed the locomotor responses of FAST and SLOW mice at postnatal days (P) 10, 15, 30, and 60. A genetically correlated response, EtOH-induced hypothermia, was also investigated. Although all animals demonstrated their respective selection phenotypes in adulthood, developing FAST mice exhibited ethanol stimulation by P15 (replicate 1) or P30 (replicate 2). At these ages, responses of FAST mice differed from those of SLOW. The stimulant response in FAST mice was adult-like at P30. EtOH-induced hypothermia was seen in SLOW mice by P15. These data suggest that sensitivity to the locomotor stimulant effects of EtOH changes during postnatal development, and may mirror developmental profiles for certain neurotransmitter systems.

Phencyclidine block of Ca2+ ATPase in rat heart sarcoplasmic reticulum

Phencyclidine hydrochloride (PCP) also known as Angel Dust is a very potent psychotomimetic drug of abuse. Besides its central nervous system (CNS) effects PCP produces a number of adverse effects in a variety of tissues including the cardiovascular system. Since PCP is known to alter the cellular calcium homeostasis the present studies were initiated to determine the changes in cardiac Ca2+ ATPase activity in rats treated with PCP. For in vitro studies the cardiac sarcoplasmic reticulum (SR) fractions prepared from normal rats were incubated with 25, 50 and 100 microM PCP and the enzyme activities were estimated. Whereas, for in vivo studies the cardiac SR fractions prepared from rats treated with PCP (10 mg/kg body wt. single dose, intra-peritoneally (i.p.)) and sacrificed at different time intervals were used. PCP reduced the Ca2+ ATPase activity significantly both in vitro and in vivo. A 50% inhibition of the enzyme activity was obtained with 100 microM PCP in vitro. A significant reduction of SR Ca2+ ATPase was also evident as early as 1 h after treatment of rats with PCP. The reduction of Ca2+ ATPase activity in SR was irreversible even at 12 h after treatment. The in vitro kinetic studies revealed that PCP was found to be a competitive inhibitor of Ca2+ ATPase with respect to the substrate, ATP, and non-competitive with respect to Ca2+ activation. These results indicate that PCP alters the myocardial Ca2+ homeostasis by inhibiting the Ca2+ ATPase in cardiac SR in rats. Inhibition of SR Ca2+ ATPase may result in the impairment of contraction and relaxation coupling processes in the myocardium.

Neurochemical and neurobehavioral effects of neonatal administration of beta-N-methylamino-L-alanine and 3,3'-iminodipropionitrile

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that is characterized by a loss of motor neurons in the spinal cord, brain stem, and cortex. The present study examined the neurochemical and neurobehavioral consequences of the neonatal administration of IDPN and BMAA, two neurotoxins previously considered as experimental models of ALS. Sprague-Dawley rat pups (male and female) were injected SC with IDPN or BMAA. The following treatment groups (n = 5-14 per group) were studied; IDPN [100 mg/kg on postnatal days (PNDs) 2, 4, and 6], BMAA-A (500 mg/kg PND 5 only), BMAA-B (500 mg/kg PND 2 and 5), and BMAA-C (100 mg/kg PND 2 and 5). Neurobehavioral testing was performed and the rats were sacrificed at 101 days of age. Monoamine and amino acid content was measured by HPLC in brain regions and the spinal cord. IDPN treatment impaired the righting reflex and decreased forepaw suspension times. BMAA-A and BMAA-B males exhibited an increase in open field behavior. The hindlimb splay of BMAA-A females was increased. Other significant behavioral and endocrine effects were also seen with neonatal IDPN or BMAA treatment. IDPN females had increased spinal cord content of norepinephrine (NE), serotonin, and 5-hydroxyindoleacetic acid (5-HIAA). IDPN males had no alterations in spinal cord content of NE or Glu, but serotonin and 5-HIAA content were increased. BMAA-A and BMAA-B males also had elevated spinal cord 5-HIAA content whereas females were unaffected. Glu and Asp content in the spinal cord was elevated in the female BMAA-C group. Monoamines were also altered in the cerebellum, mediobasal hypothalamus, and hippocampus by IDPN and BMAA treatment. alpha 2-Adrenergic binding sites were increased in the spinal cord by IDPN and in the cerebellum by BMAA treatment. The results of this study clearly demonstrated that both IDPN and BMAA given neonatally can produce changes in motor function and spinal cord neurochemistry, although the pattern of the effects is both treatment and sex dependent. Neonatal exposure to either IDPN or BMAA resulted in permanent changes in adult neurochemistry that may be related to reorganizational effects induced by toxin-mediated neuroplasticity in developing neurons.

Perinatal bupivacaine and infant behavior in rhesus monkeys

To assess the effect of perinatal epidural bupivacaine analgesia on infant behavioral development, bupivacaine (1.2 mg/kg) was administered to term-pregnant rhesus monkeys (treated, n = 11, procedural controls, n = 8) and infant behavior was evaluated for 1 year using a test battery including infant neurobehavioral tests, observation of spontaneous behavior, and structured cognitive testing. No adverse effects of bupivacaine were detected for neonatal neurobehavior, early cognitive abilities, or performance of cognitive tasks by older infants. Bupivacaine infants directed more, shorter fixations at visual stimuli during visual novelty preference testing. Observation of behavior maturation patterns showed that the increase in manipulatory activity that normally occurs at 2 months of age was delayed in bupivacaine infants, and the increase in motor disturbance behaviors that normally occurs at 10 months of age was prolonged. These results are interpreted in terms of life-history and brain maturation landmarks that appear at these ages. The data suggest that epidural bupivacaine does not cause neonatal abnormalities or specific cognitive deficits but can alter the normal course of behavioral development.

Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response

Methamphetamine (MA) administration to adult rats results in neurotoxicity characterized by depletion of caudate-putamen (CP) dopamine (DA) and serotonin (5-HT) and an accompanying increase in glial fibrillary acidic protein (GFAP) content. The severity of MA-induced neurotoxicity correlates with the accompanying thermoregulatory response, i.e., a hyperthermic response facilitates neurotoxicity while a hypothermic response is neuroprotective. In the following study, the thermoregulatory and neurotoxic effects of MA administration (4 x 10 mg/kg) were investigated in developing rats at postnatal days (PND) 20, 40 and 60. Rats at PND 20 and PND 40 were administered MA at ambient temperatures of 22 degrees C and 30 degrees C; and PND 60 rats were administered MA at 22 degrees C only. Temperatures were measured and thermal responses were compared by calculating the total thermal response (TTR) induced by MA treatment. MA administration to PND 60 rats at 22 degrees C induced a hyperthermic response, resulted in a 47% reduction of neostriatal DA and a 49% increase of GFAP content. Administration of MA to PND 40 rats at 22 degrees C failed to induce a hyperthermic response and did not result in reduced DA or increased GFAP. However, administration of MA to PND 40 rats at 30 degrees C induced hyperthermia, reduced neostriatal DA by 54% and increased GFAP by 70%. MA administration to PND 20 rats at either 22 degrees C or 30 degrees C did not result in DA depletion or increased GFAP, even though MA administration to PND 20 rats at 30 degrees C induced hyperthermia. These results demonstrate that the induction of hyperthermia is necessary to exhibit MA-induced neurotoxicity at PND 40; however, PND 20 rats are resistant to the DA depleting effects of MA despite the induction of hyperthermia.

Labor analgesia and infant brain development

A large percentage of newborns are exposed to pharmacological agents that affect the brain in connection with pain management during labor. The two most commonly used agents are meperidine, administered intravenously or intramuscularly, and bupivacaine, administered by the epidural route. Over the years, infant behavioral assessments have been used in the neonatal nursery to identify labor analgesia regimens with minimal impact on neonatal status. However, considerable controversy has centered on the general issue of possible harm to the neonate from use of analgesia and anesthesia in obstetrics. Due to limitations on experiments in the obstetric situation and a lack of suitable animal models, the broader issues concerning the effects of these agents on the developing brain and possible long-term consequences for infant adaptive functioning have received little attention. A series of studies has recently been completed using a rhesus monkey model for administration of labor analgesia under controlled experimental conditions and long-term behavioral evaluation of infants. Most of the assessments, including those of cognitive function, were not influenced by perinatal analgesia. However, these studies have confirmed the neonatal depressant effects of meperidine and have suggested that the course of behavioral maturation during certain periods of infancy is influenced by both meperidine and bupivacaine administration at birth. These effects could occur as a result of effects on vulnerable brain processes during a sensitive period, interference with programming of brain development by endogenous agents, or alteration in early experiences.

Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine

To investigate the in vivo role of NMDA receptor stimulation in HIV-1-related CNS neurotoxicity, we evaluated the neuroprotective potential of the NMDA receptor antagonist memantine in transgenic mice which have gp120-induced CNS damage. Brains of mice treated chronically with memantine and of untreated controls were analysed for structural damage by laser scanning confocal microscopy of sections immunolabeled for microtubule-associated protein-2 (MAP-2) and synaptophysin. Qualitative and quantitative analysis of confocal images revealed that memantine treatment substantially decreased neuropathology in gp120 transgenic mice; this included statistically significant improvements in both dendritic and presynaptic terminal density. These results provide in vivo evidence that gp120 can activate neurotoxic pathways that can ultimately result in aberrant NMDA receptor stimulation and neuronal damage in the CNS. They also suggest that clinically tolerated NMDA receptor antagonists may be useful in the prevention of neuronal damage in HIV-1-infected patients.

Dizocilpine binding to cerebral cortical membranes from developing and ageing mice

The binding of [3H]dizocilpine (MK-801) to the N-methyl-D-aspartate (NMDA)-gated ion channel was characterized in cerebral cortical membranes during the major portion of the mouse life-span (from 7-day- to 22-month-olds). The binding was saturable, consisting of only one component at all ages studied. The maximal binding capacity Bmax was very substantial in 14-day-old mice when compared to adults (3-month-olds), decreasing thereafter during ageing. The binding constant KD remained unchanged during development and increased only slightly in aged mice. Glutamate and glycine potentiated dizocilpine binding concentration-dependently. Their efficacy varied markedly with age. Both glutamate and glycine had considerably less effect on the immature cerebral cortex and in the oldest group of mice (22-month-old) than in young adults. The marked increase in dizocilpine binding sites at the age of 2 weeks coincides with the previously reported transient increase in NMDA binding sites in the cerebral cortex. The weak potentiation of dizocilpine binding by glutamate and glycine in the immature brain could be a factor which protects neurons during this period from excitotoxicity and increased susceptibility to seizures induced by acidic amino acids. The decrease in the number of dizocilpine binding sites during ageing could result partly from the loss of cortical neurons.

The effects of reduced perfusion and reperfusion on c-fos and HSP-72 protein immunohistochemistry in gestational day 21 rat brains

Metabolic stressors such as hyperthermia, seizures and ischemic hypoxia result in the induction of c-fos and heat-shock proteins (HSP) in affected brain cells of the adult rodent, especially within the hippocampal region, which normally has high metabolic demands. Here we ligated the uterine vessels of gestational day (GD) 21 rat pups to produce ischemic hypoxia. We confirmed that HSP-72 protein, as previously reported, was activated in the perinatal rat pup, especially in the hippocampal CA3 region. However, the capability of hippocampal cells to produce c-fos protein following drug-induced seizures has been reported to develop only after postnatal day 13. Here, ischemic hypoxia caused CA1 hippocampal cells to produce immunohistochemically detectable c-fos protein in GD-21 rats. These results seem to contradict the previous reports of no c-fos induction in rats this young by demonstrating a functional c-fos translational mechanism by GD-21. However, seizure vs ischemic hypoxia-induced c-fos expression may involve several different pre-translational pathways. A delayed development of a receptor, second messenger, or genomic element for regulating c-fos transcription remain as possible explanations for the late maturity of responsivity to seizures.